CA3065919A1 - Conjugues de construction d'anticorps - Google Patents
Conjugues de construction d'anticorps Download PDFInfo
- Publication number
- CA3065919A1 CA3065919A1 CA3065919A CA3065919A CA3065919A1 CA 3065919 A1 CA3065919 A1 CA 3065919A1 CA 3065919 A CA3065919 A CA 3065919A CA 3065919 A CA3065919 A CA 3065919A CA 3065919 A1 CA3065919 A1 CA 3065919A1
- Authority
- CA
- Canada
- Prior art keywords
- immune
- amino acid
- conjugate
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Abstract
Diverses compositions sont décrites. L'invention concerne également des compositions de conjugués composition-composé stimulateur immunitaire. L'invention concerne en outre les procédés de préparation et les utilisations de ces conjugués composition-composé stimulateur immunitaire. L'invention inclut des méthodes de traitement d'affections telles que le cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762516667P | 2017-06-07 | 2017-06-07 | |
US62/516,667 | 2017-06-07 | ||
PCT/US2018/036560 WO2018227023A1 (fr) | 2017-06-07 | 2018-06-07 | Conjugués de construction d'anticorps |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3065919A1 true CA3065919A1 (fr) | 2018-12-13 |
Family
ID=64566685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3065919A Abandoned CA3065919A1 (fr) | 2017-06-07 | 2018-06-07 | Conjugues de construction d'anticorps |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3634401A1 (fr) |
CA (1) | CA3065919A1 (fr) |
WO (1) | WO2018227023A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111337685A (zh) * | 2020-02-28 | 2020-06-26 | 苏州卫生职业技术学院 | 可溶性pd-l2作为sle生物标志物的应用 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018009916A1 (fr) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugués d'adjuvant d'anticorps |
WO2018067702A1 (fr) | 2016-10-04 | 2018-04-12 | Massachusetts Institute Of Technology | Copolymères en forme de goupillon et leurs utilisations |
WO2019118884A1 (fr) * | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Conjugué de construction d'anticorps-médicament pour le traitement de l'hépatite |
KR20200099123A (ko) * | 2017-12-15 | 2020-08-21 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 생체활성 접합체, 이의 제조 방법 및 용도 |
CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
AU2019365238A1 (en) * | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
EP3693023A1 (fr) * | 2019-02-11 | 2020-08-12 | Sanofi | Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon |
CA3129106A1 (fr) * | 2019-02-07 | 2020-08-13 | Sanofi | Utilisation d'immunoconjugues anti-ceacam5 pour le traitement du cancer du poumon |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
JP2022543086A (ja) | 2019-08-02 | 2022-10-07 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のSTING(インターフェロン遺伝子刺激因子)アゴニストとしてのビス-[N-((5-カルバモイル)-1H-ベンゾ[d]イミダゾール-2-イル)-ピラゾール-5-カルボキサミド]誘導体および関連化合物 |
US11752197B2 (en) | 2019-08-12 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (MST1R) variants and uses thereof |
WO2021072203A1 (fr) * | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Conjugués inhibiteur de tgfbetar1-anticorps anti-asgr et utilisations associées |
US20210220391A1 (en) * | 2020-01-10 | 2021-07-22 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
WO2021168274A1 (fr) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
IL296124A (en) * | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
KR20240029062A (ko) | 2021-07-02 | 2024-03-05 | 메르크 파텐트 게엠베하 | 항-protac 항체 및 복합체 |
CN113512117B (zh) * | 2021-07-12 | 2023-08-22 | 武汉麦考津生物科技有限公司 | 一种可结合cd206的抗体及其应用 |
CN113563464B (zh) * | 2021-08-01 | 2023-02-03 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 人源化高中和活性抗新型冠状病毒单克隆抗体及应用 |
WO2023056069A1 (fr) * | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2932874T3 (es) * | 2009-03-25 | 2023-01-27 | Genentech Inc | Anticuerpos anti-FGFR3 y métodos que utilizan los mismos |
US20120064097A1 (en) * | 2010-07-20 | 2012-03-15 | Washburn Newell R | Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates |
DK3191135T3 (da) * | 2014-09-12 | 2020-10-12 | Genentech Inc | Anti-HER2-antistoffer og immunokonjugater |
US20180100026A1 (en) * | 2015-04-15 | 2018-04-12 | California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
RU2018120330A (ru) * | 2015-11-02 | 2019-12-04 | Йейл Юниверсити | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения |
US20170158772A1 (en) * | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
PL3458101T3 (pl) * | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
-
2018
- 2018-06-07 CA CA3065919A patent/CA3065919A1/fr not_active Abandoned
- 2018-06-07 EP EP18814341.6A patent/EP3634401A1/fr not_active Withdrawn
- 2018-06-07 WO PCT/US2018/036560 patent/WO2018227023A1/fr unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111337685A (zh) * | 2020-02-28 | 2020-06-26 | 苏州卫生职业技术学院 | 可溶性pd-l2作为sle生物标志物的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2018227023A1 (fr) | 2018-12-13 |
EP3634401A1 (fr) | 2020-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3065919A1 (fr) | Conjugues de construction d'anticorps | |
US20210115109A1 (en) | Conjugates and methods of use thereof for selective delivery of immune-modulatory agents | |
ES2910365T3 (es) | Nuevos polipéptidos biespecíficos contra CD137 | |
US20230295325A1 (en) | Novel anti-cd137 antibodies and uses thereof | |
US20190336615A1 (en) | Tumor targeting conjugates and methods of use thereof | |
US20200199242A1 (en) | Construct-peptide compositions and methods of use thereof | |
CA3168832A1 (fr) | Anticorps cd28 a domaine unique et constructions multivalentes et multispecifiques de ceux-ci | |
TW201737941A (zh) | 新穎的b7-h3-結合分子、其抗體藥物綴合物及其使用方法 | |
WO2020076970A1 (fr) | Anticorps b7h3 à domaine unique et compositions thérapeutiques associées | |
JP2022512653A (ja) | Pd-1単一ドメイン抗体およびその治療用組成物 | |
JP2022500404A (ja) | 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用 | |
JP2022504826A (ja) | 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 | |
EP3864045A2 (fr) | Anticorps à domaine unique dll3 et compositions thérapeutiques | |
CN114341185A (zh) | 抗间皮素抗体及其免疫缀合物 | |
JP2023547380A (ja) | 新規の抗lilrb2抗体および誘導体生成物 | |
US20220306752A1 (en) | Epha2 antibodies | |
TW202309088A (zh) | 新的穩定抗vista抗體 | |
CA3146977A1 (fr) | Constructions d'anticorps se liant a 4-1bb et recepteurs alpha de folate et leurs utilisations | |
CA3226306A1 (fr) | Nouvelles molecules multi-specifiques | |
WO2023196869A1 (fr) | Anticorps anti-epha2 | |
WO2023094995A1 (fr) | Anticorps humains cxcl16 et leur utilisation | |
JP2023518189A (ja) | デルタ鎖媒介性免疫を調節するための材料及び方法 | |
CN118055946A (zh) | 新型多特异性分子 | |
NZ787254A (en) | Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20220301 |